NCT06391775 - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions

Malignant Solid Tumor

Interventions

BIOLOGICAL

GEN1055

Intravenous (IV) administration.

BIOLOGICAL

Pembrolizumab

IV administration

DRUG

Standard Chemotherapy

IV administration

Trial Locations (4)

Clinica Universidad de Navarra, Pamplona

Yale-New Haven Hospital, New Haven

Hospital Universtari Val D´Hebron, Barcelona

Start Madrid Ciocc Hm Sanchinarro, Madrid